{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:03:25Z","timestamp":1791558205458,"version":"4.3.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2016,8,8]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      Urinary 11\u2010dehydro\u2010thromboxane (\n                      <jats:styled-content style=\"fixed-case\">TX<\/jats:styled-content>\n                      )B\n                      <jats:sub>2<\/jats:sub>\n                      has been described as a potential predictive biomarker of major adverse cardiovascular events (\n                      <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>\n                      s) in high cardiac risk patients. This part of\n                      <jats:styled-content style=\"fixed-case\">LTIMI<\/jats:styled-content>\n                      (Leukotrienes and Thromboxane In Myocardial Infarction) study aimed to evaluate the relationship between 11\u2010dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      and\n                      <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>\n                      s in patients with acute myocardial infarction (\n                      <jats:styled-content style=\"fixed-case\">AMI<\/jats:styled-content>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods and Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      <jats:styled-content style=\"fixed-case\">LTIMI<\/jats:styled-content>\n                      was an observational, prospective study in 180 consecutive patients with\n                      <jats:styled-content style=\"fixed-case\">AMI<\/jats:styled-content>\n                      type 1 referred for primary percutaneous coronary intervention. On admission and at follow\u2010up visits (1 month, 1 year), 11\u2010dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      was measured in urinary samples by using high\u2010performance liquid chromatography\u2013tandem mass spectrometry. The primary outcome was occurrence of composite\n                      <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>\n                      s during 1\u2010year after\n                      <jats:styled-content style=\"fixed-case\">AMI<\/jats:styled-content>\n                      . Left ventricular ejection fraction was assessed in echocardiography on admission and at 1\u2010year follow\u2010up. Analyses of 11\u2010dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      (pg\/mg creatinine) were performed on log\u2010transformed data and expressed as median with\n                      <jats:styled-content style=\"fixed-case\">IQR<\/jats:styled-content>\n                      (Q1\u2013Q3). 11\u2010Dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      level on admission was 7.39 (6.85\u20138.01) and decreased at 1 month (6.73, 6.27\u20137.12;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001) and 1\u2010year follow\u2010up (6.37, 5.91\u20136.94;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001). In univariate analysis, baseline 11\u2010dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      was higher in patients with\n                      <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>\n                      s (n=60; 7.73, 7.07\u20138.60) compared with those without\n                      <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>\n                      s (n=119; 7.28, 6.68\u20137.79;\n                      <jats:italic>P<\/jats:italic>\n                      =0.002). In multivariate regression model, 11\u2010dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      and 3 other variables (diabetes, multivessel disease, and left ventricular ejection fraction) were found to be best 1\u2010year cumulative\n                      <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>\n                      predictors with odds ratio for 11\u2010dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      of 1.58 (95%\n                      <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n                      1.095\u20132.33;\n                      <jats:italic>P<\/jats:italic>\n                      =0.017) and area under the curve (in receiver operating characteristic analysis of 0.8). Baseline 11\u2010dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      negatively correlated with both left ventricular ejection fraction on admission (\n                      <jats:italic>R<\/jats:italic>\n                      =\u22120.21;\n                      <jats:italic>P<\/jats:italic>\n                      =0.006) and after 1 year (\n                      <jats:italic>R<\/jats:italic>\n                      =\u22120.346;\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">\n                      11\u2010Dehydro\u2010\n                      <jats:styled-content style=\"fixed-case\">TXB<\/jats:styled-content>\n                      <jats:sub>2<\/jats:sub>\n                      predicts 1\u2010year cumulative\n                      <jats:styled-content style=\"fixed-case\">MACE<\/jats:styled-content>\n                      s in\n                      <jats:styled-content style=\"fixed-case\">AMI<\/jats:styled-content>\n                      patients and provides prognostic information on the left ventricular performance.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.116.003702","type":"journal-article","created":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T22:29:04Z","timestamp":1470090544000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Urinary 11\u2010Dehydro\u2010Thromboxane B\n                    <sub>2<\/sub>\n                    as a Predictor of Acute Myocardial Infarction Outcomes: Results of Leukotrienes and Thromboxane In Myocardial Infarction (LTIMI) Study"],"prefix":"10.1161","volume":"5","author":[{"given":"Wojciech","family":"Szczeklik","sequence":"first","affiliation":[{"name":"Department of Medicine, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edyta","family":"Stod\u00f3\u0142kiewicz","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Rzeszutko","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Tomala","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Chrustowicz","sequence":"additional","affiliation":[{"name":"Noninvasive Cardiovascular Laboratory, John Paul II Hospital, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"\u017bmudka","sequence":"additional","affiliation":[{"name":"Department of Interventional Cardiology, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Sanak","sequence":"additional","affiliation":[{"name":"Department of Medicine, Jagiellonian University Medical College, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1102-1227"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052717"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2008.03184.x"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12026"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)68855-1"},{"key":"e_1_3_5_7_2","first-page":"I12","article-title":"Biosynthesis and pharmacological modulation of thromboxane in humans","volume":"81","author":"Patrono C","year":"1990","unstructured":"Patrono C. Biosynthesis and pharmacological modulation of thromboxane in humans. Circulation. 1990;81:I12\u2013I15; discussion I22\u201013.","journal-title":"Circulation"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112341"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn562"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000013777.21160.07"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.768283"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198610163151602"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.1994.tb01049.x"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39430.529549.BE"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.08.650"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.187397"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31826e1058"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2010.05.012"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.echo.2005.10.005"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2012.07.020"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000043260.82447.62"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.04.158"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-010-0621-6"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.107.160481"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-3848(01)00339-5"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio0728"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.900589"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.838888"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.07.985"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.07.058"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH11-09-0635"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2009.06.004"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn325"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.116.003702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T06:20:07Z","timestamp":1715581207000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.116.003702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8,8]]}},"alternative-id":["10.1161\/JAHA.116.003702"],"URL":"https:\/\/doi.org\/10.1161\/jaha.116.003702","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]},"assertion":[{"value":"2016-04-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-15","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-08-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e003702"}}